AGIX is up 11.3% after some news
bigcharts.marketwatch.com
AtheroGenics Announces Five Abstracts Accepted for the American Diabetes Association's 68th Annual Scientific Sessions
Wednesday June 4, 7:30 am ET
ATLANTA, GA--(MARKET WIRE)--Jun 4, 2008 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that five abstracts, which describe both clinical and pre-clinical diabetes and cardiovascular data from studies of its novel drug candidate, AGI-1067, have been accepted for the American Diabetes Association's (ADA) 68th Scientific Sessions taking place at the Moscone Convention Center in San Francisco, Calif. from June 6-10, 2008.
A "Late Breaking Clinical Studies" oral presentation entitled, "Delay in Progression to Type 2 Diabetes in Patients with Cardiovascular Disease Treated with a Novel Anti-Inflammatory, Anti-Oxidant, AGI-1067: Evidence from ARISE," is scheduled for Monday, June 9, at 5:00 p.m. PT by Jean-Claude Tardif, M.D., Director of Research, Professor of Medicine, Montreal Heart Institute, University of Montreal.
The ADA's Annual Scientific Sessions is the nation's largest meeting for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care.
Other AtheroGenics abstracts include:
-- "AGI-1067 Improves Glycemic Control When Added to Current Regimens in Patients with Type 2 Diabetes." This poster, 443-P, will be presented by Eric Klug, M.D., Sunninghill Hospital, Sunninghill, Gauteng, South Africa,and will be displayed from Saturday, June 7, through Monday, June 9, 2008in the Poster Hall.
"Effects of AGI-1067 on Cardiovascular (CV) Risk in Patients with Type
2 Diabetes or Impaired Fasting Glucose (IFG) in the ARISE Trial." This abstract, 2065-PO, by lead author John J.McMurray, M.D., Professor of Medical Cardiology, University of Glasgow, and Honorary Consultant Cardiologist, Western Infirmary, Glasgow, Scotland, was accepted for publication in the ADA Scientific Sessions Abstract Book.
"AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Improves Insulin Sensitivity in a Rat Model of Diet-Induced Obesity," Cynthia L.Sundell, Ph.D., Vice President of Pharmacology, AtheroGenics. This poster,345-P, will be displayed from Saturday, June 7 through Monday, June 9, 2008 in the Poster Hall.
"AGI-1067, a Novel Antioxidant and Anti-Inflammatory Agent, Inhibits Activation of JNK, IRS-1 Serine Phosphorylation and Cytokine Production in Adipocytes," Xilin Chen, Ph.D., Senior Principal Scientist, AtheroGenics.This poster, 1262-P, will be displayed from Saturday, June 7 through Monday, June 9, 2008 in the Poster Hall.
Snip
Bernard |
